H.C. Wainwright raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $37 from $32 and keeps a Buy rating on the shares following the approval of Daybue Stix. The approval unlocks access for patients who previously couldn’t swallow the large liquid volumes, the analyst tells investors in a research note. The firm’s key opinion leader analysis suggests the powder formulation could reduce stomach issues by removing specific additives, while solving the taste struggles that cause families to stop treatment.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals announces FDA approval of Daybue Stix for oral solution
- Acadia Pharmaceuticals price target raised to $25 from $24 at Stifel
- Acadia Pharmaceuticals price target raised to $29 from $24 at Mizuho
- Acadia Pharmaceuticals price target lowered to $31 from $33 at JPMorgan
- ACADIA Pharmaceuticals: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating